Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Request For Predictable NIH Funding Growth Met By Spending Caps

This article was originally published in The Tan Sheet

Executive Summary

The best way to accelerate medical cures, National Institutes of Health Director Francis Collins tells the congressional 21st Century Cures coalition, is to assure that NIH researchers are supplied with a steady, predictable source of grant funding.

You may also be interested in...



Decline In U.S. Medical Funding Is Compromising Future Innovation, Study Says

A study in the Journal of American Medical Association says that the U.S. contribution to global biomedical research funding is on the decline, which could have big implications for domestic innovation.

Decline In U.S. Medical Funding Is Compromising Future Innovation, Study Says

A study in the most recent issue of JAMA shows that the U.S. contribution to biomedical research funding is on the decline and may result in decreased innovation, should other funding sources not be found.

Shuren Highlights CDRH Actions To Ease Trial Burdens On Capitol Hill

CDRH Director Jeffrey Shuren participated in the first roundtable of a newly launched House Energy and Commerce Committee initiative to accelerate drug and device development. He emphasized the device center’s recent proposals to minimize pre-market data collection with postmarket controls, and supported the promise of clinical trial networks.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel